ArticleCancer reports (Hoboken, N.J.)2026
Significance and Correlation Analysis of Folate Receptor-Positive Circulating Tumor Cells (FR + CTC) in Colorectal Cancer Patients.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Significance and Correlation Analysis of Folate Receptor-Positive Circulating Tumor Cells (FR + CTC) in Colorectal Cancer Patients.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the significance of detecting folate receptor-positive circulating tumor cells (FR + CTC) in colorectal cancer patients and to analyze their correlation with the expression of conventional tumor markers (CEA, CA199, CA125). METHODS AND
resultsA retrospective collection of preoperative FR + CTC values from patients in the Gastrointestinal Surgery Department of Henan Provincial People's Hospital between July 2021 and May 2023 was conducted. The area under the ROC curve was used to assess the accuracy of FR + CTC values and the expression levels of conventional tumor markers (CEA, CA199, CA125) in diagnosing colorectal cancer patients with peritoneal metastasis, lymph node metastasis, vascular invasion, nerve invasion, and tumor penetration of the serosal layer (T3-4). Spearman correlation analysis was used to study the correlation between FR + CTC values and the expression levels of CEA, CA199, and CA125. Non-parametric tests were used to study the differences in CTC values, CEA, CA199, and CA125 among different types of colorectal cancer patients. A total of 273 colorectal cancer patients with preoperative FR + CTC detection were included in the study. Among these, 19 patients (7.0%) had peritoneal metastasis. The areas under the ROC curve for diagnosing colorectal cancer patients with peritoneal metastasis, lymph node metastasis, vascular invasion, nerve invasion, and tumor penetration of the serosal layer (T3-4) using FR + CTC were 0.828, 0.617, 0.651, 0.642, and 0.622, respectively, all of which were higher than those of conventional tumor markers (CEA, CA199, CA125). The optimal FR + CTC cut-off value for diagnosing peritoneal metastasis was 14.0 FU/3 mL, with a sensitivity of 80.5% and a specificity of 85.2%. There was a statistically significant correlation between FR + CTC values and CA125 expression levels (correlation coefficient R = 0.15, p = 0.015), while no significant correlation was found between FR + CTC values and the expression levels of CEA and CA199. The detection values of FR + CTC were higher in colorectal cancer patients with peritoneal metastasis, lymph node metastasis, vascular invasion, nerve invasion, and tumor penetration of the serosal layer (T3-4), with statistically significant differences (p < 0.05).
conclusionFR + CTC values can serve as a new tumor marker for colorectal cancer patients, offering stronger clinical guidance than traditional gastrointestinal tumor markers (CEA, CA199, CA125). Future research should focus on validating these results in multicenter prospective cohorts and exploring the integrative value of FR + CTC with other liquid biopsy markers like ctDNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.